Vijaypd Ceutical Limited Link 
Allotment
The Vijaypd Ceutical IPO will open for subscription on September 29, 2025, and close on October 1, 2025. The IPO is a fixed price issue through which the company aims to raise approximately ₹19.25 crore. The issue comprises a fresh issue aggregating ₹19.25 crore along with an offer for sale of up to [●] equity shares, each having a face value of ₹10.
The IPO is priced at ₹35 per share, with 50% of the issue reserved for retail investors and 50% for High Net-worth Individuals (HNIs), while no portion is allocated to Qualified Institutional Buyers (QIBs).
The basis of allotment is expected to be finalized on October 3, 2025, and the equity shares are scheduled to be listed on the NSE on October 7, 2025.
On the financial front, Vijaypd Ceutical reported revenue of ₹107.59 crore in FY2025, compared to ₹54.34 crore in FY2024. Net profit rose to ₹4.80 crore in FY2025 from ₹1.65 crore in the previous year. Based on the company’s strong growth in revenue and profitability, the IPO may be suitable for investors with a long-term investment perspective.
₹35
0%
Open
₹35
HIgh - Low
₹35
Previous Close
₹35
Total Traded Value
0
52 Weeks High
₹35
52 Weeks Low
₹35
Updates On
Sep 22, 2025
IPO. Open
Sep 29, 2026
IPO. Close
Oct 1, 2026
IPO. Price
₹35.00
IPO Market price
To be declared
IPO Details
| IPO Date | 7 Oct |
| IPO Listing Date | 7 Oct |
| IPO Face Value | ₹10 per share |
| IPO Price Range | ₹35.00 |
| IPO Issue Size | 55,00,000 shares |
| IPO Sale Type | Fresh Capital |
| Employee Discount | - |
| IPO Issue Type | Fixed Price |
| IPO Listing | NSE SME Platform |
| hare Holding Pre Issue | 1,40,28,686 |
IPO Timeline
| IPO Open Date | 29 Sep |
| IPO Close Date | 1 Oct |
| IPO Allotment (Tentative) | 3 Oct |
| Refunds | 6 Oct |
| Credit to Demat Account | 6 Oct |
| IPO Listing Date | 7 Oct |
IPO Reservation
| Category | Offer |
|---|---|
| QIB Shares Offered | - |
| NII (HNI) Shares Offered | 26,08,000 |
| Retail Shares Offered | 26,08,000 |
IPO Lot Size
Investors can bid for a minimum of 8,000 shares, with additional shares available in multiples of 4,000.
| Application | Lots | Share | Amount |
|---|---|---|---|
| Retail (Min) | 2 | 8,000 | ₹2,80,000 |
| Retail (Max) | 2 | 8,000 | ₹2,80,000 |
| S-HNI (Min) | 3 | 12,000 | ₹4,20,000 |
| S-HNI (Max) | - | - | - |
| B-HNI (Min) | - | - | - |
Incorporated in October 1971, Vijaypd Ceutical Limited is a pharmaceutical and consumer goods distributor offering a wide range of products and services. The company operates as representatives, dealers, agents, stockists, suppliers, traders, and packers, serving the pharmaceutical, wellness, and FMCG sectors.
Vijaypd Ceutical’s product portfolio includes medicines such as injections, tablets, capsules, ointments, suppositories, ophthalmic preparations, and liquid oral products, along with vitamins, hormones, enzymes, wellness tonics, serums, diagnostic test kits, personal care items (soaps, sanitizers, baby care), ayurvedic products, cosmetics, food products, dental products, and crude drugs.
As of March 31, 2025, the company serves over 2,109 pharmacies, clinics, and nursing homes across four districts, covering 20 locations. Its distribution network connects with more than 170 healthcare product manufacturers, providing access to over 19,000 SKUs. This extensive network and product range enable the company to meet diverse customer needs while ensuring quality, reliability, and timely delivery of pharmaceutical products.
Vijaypd Ceutical is certified by the FDA, FSSAI, and BMC, reflecting its commitment to quality, compliance, and operational standards.
Competitive Strengths:
Strong and long-standing relationships with clients, strengthening market position
Comprehensive and diversified product portfolio across pharmaceuticals, wellness, and FMCG
Efficient supply chain management ensuring timely and reliable distribution
Experienced management team with proven execution capabilities
Company Financials (Consolidated)
| Assets | 57.15 | 33.27 | 32.87 |
| Total Income | 107.59 | 54.34 | 50.59 |
| Profit After Tax | 4.8 | 1.65 | 0.18 |
| EBITDA | 8.59 | 4.87 | 1.32 |
| NET Worth | 32.17 | 1 | 4.93 |
| Reserves and Surplus | 18.14 | - | - |
| Total Borrowing | 21.77 | 30.04 | 25.56 |
Key Performance Indicator (KPI
| ROE | 28.91% |
| ROCE | 17.30% |
| Debt/Equity | 0.68 |
| RoNW | 14.91% |
| PAT Margin | 4.49% |
| EBITDA Margin | 8.04% |
| Price to Book Value | - |
IPO Objects of the Issue
| S.No. | Objects of the ipo Resources Detail | IPO Amount |
|---|---|---|
| 1 | Funding capital expenditure requirements for the purchase of equipment/machineries | 10.83 |
| 2 | To meet out the expenses of Working Capital Requirement | - |
| 3 | To meet out the General Corporate Purposes; | 0.74 |
| 4 | Offer for Sale (OFS) | - |
Contact Details
Vijaypd Ceutical Ltd. Address
A/1, 1st Floor
Devraj Premises
CHSL, Goregaon West
Mumbai, Maharashtra, 400062
Phone: +91 9820917040
Email: investors@vijaypdceutical.com
Website: https://www.vijaypdceutical.com/
Detail Registrar
Kfin Technologies Limited
Selenium Tower-B Plot No. 31 &
32 Gachibowli, Financial District,
Nanakramguda Serilingampally,
Hyderabad – 500032, Telangana, India
Phone: 04067162222, 04079611000
Email: vcl.ipo@kfintech.com
Website: https://ipostatus.kfintech.com/
The Vijaypd Ceutical Limited IPO opened on September 29, 2025, and closed on October 1, 2025. The shares were listed on the NSE SME platform on October 7, 2025.
The IPO was a fixed price issue at ₹35 per share with a face value of ₹10. The total issue comprised 55,00,000 shares aggregating up to approximately ₹19 crore.
Retail investors were required to apply for a minimum of 8,000 shares, equivalent to 2 lots. The minimum investment amount was ₹2,80,000 at the issue price of ₹35 per share.
The IPO allocation was equally divided, with 50% reserved for Retail investors and 50% for High Net-worth Individuals (HNIs). No portion was allocated to Qualified Institutional Buyers (QIBs).
For FY2025, the company reported total income of ₹107.59 crore and profit after tax of ₹4.80 crore, showing strong growth compared to FY2024.
The company planned to utilize IPO proceeds for setting up a pharmaceutical API and intermediates manufacturing plant, purchasing machinery, repaying borrowings, and general corporate purposes.
As of March 31, 2025, the company reported ROE of 28.91%, ROCE of 17.30%, PAT margin of 4.49%, EBITDA margin of 8.04%, and a Debt/Equity ratio of 0.68.
Compare:
